Cardiopulmonary bypass induced inflammation: Pathophysiology and treatment. An update

European Journal of Cardio-thoracic Surgery

Volumn 21, Issue 2, 2002, Pages 232-244

  Paparella, D ^a   Yau, T M ^a   Young, E ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

Acute phase reaction; Cardiopulmonary bypass; Cytokine; Heparin; Inflammation; Nuclear factor kB

Indexed keywords

ANAPHYLATOXIN; ANTIOXIDANT; APROTININ; CELL ADHESION MOLECULE; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C5A; CYCLIC AMP; CYTOKINE; GLUCOCORTICOID; HEPARIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTEGRIN; INTERLEUKIN 1BETA; KALLIKREIN; MEMBRANE PROTEIN; NITRIC OXIDE SYNTHASE; NITROPRUSSIDE SODIUM; PHOSPHODIESTERASE INHIBITOR; PROTAMINE; PROTEINASE INHIBITOR; SPHINGOSINE; THROMBIN; TUMOR NECROSIS FACTOR ALPHA;

ACUTE PHASE RESPONSE; CARDIOPULMONARY BYPASS; CELL ACTIVATION; COMPLEMENT ACTIVATION; ENDOTHELIUM CELL; ENDOTOXEMIA; EXTRACORPOREAL CIRCULATION; HEART SURGERY; HUMAN; INFLAMMATION; LEUKOCYTE ACTIVATION; MUSCLE ISCHEMIA; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; REVIEW; SURGICAL TECHNIQUE;

ACUTE-PHASE REACTION; CARDIOPULMONARY BYPASS; CYTOKINES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INFLAMMATION MEDIATORS; MALE; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS;

EID: 0036168128     PISSN: 10107940     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1010-7940(01)01099-5     Document Type: Review

References (131)

1. Complement activation in coronary artery bypass grafting patients without cardiopulmonary bypass
2. Complement activation during cardiopulmonary bypass: evidence for generation of C3a and C5a anaphylotoxins
3. Activation of the complement system during and after cardiopulmonary bypass surgery: postsurgery activation involves C-reactive protein and is associated with postoperative arrhythmia
4. x-glycosylated complement inhibitory protein
5. A new biologic role for C3a and C3a desArg: regulation of TNF-α and IL-1β synthesis
6. Regulation of IL-6 synthesis in human peripheral blood mononuclear cells by C3a and C3a(desArg)
7. Cytokine mRNA expression in human platelets and a megakaryocytic cell line and cytokine modulation of platelet function
8. Cytokine activation of endothelial cells: new molecules for an old paradigm
9. Steroid inhibition of cytokine-mediated vasodilation after warm heart surgery
10. Inhibition of IL-10 expression by IFN-gamma up-regulates transcription of TNF-alpha in human monocytes
11. Tumor necrosis factor-alpha and inteleukin-1beta synergistically depress human myocardial function
12. TNF-α causes reversible in vivo systemic vascular barrier dysfunction via NO-dependent and -independent mechanisms
13. Role of TNF in mediating renal insufficiency following cardiac surgery: evidence of a postbypass cardiorenal syndrome
14. Mediators of septic shock: new approaches for interrupting the endogenous inflammatory cascade
15. Bacterial lipopolysaccharide and inflammatory mediators augment IL-6 secretion by human endothelial cells
16. Association between gastric intramucosal ph and splanchnic endotoxin, antibody to endotoxin, and tumor necrosis factor-α concentration in patients undergoing cardiopulmonary bypass
17. Intestinal permeability, gastric intramucosal ph, and systemic endotoxemia in patients undergoing cardiopulmonary bypass
18. Preoperative and postoperative endotoxemia in children with congenital heart disease
19. Mechanisms of disease: the L-arginin-nitric oxide pathway
20. Role of nitric oxide and peroxynitrite in the cytokine-induced sustained myocardial dysfunction in dogs in vivo
21. Basal nitric oxide expresses endogenous cardioprotection during reperfusion by inhibition of neutrophil-mediated damage after surgical revascularization
22. Constitutive nitric oxide release is impaired after ischemia and reperfusion
23. Nuclear factor k B: a pivotal role in the systemic inflammatory response syndrome and new target for therapy
24. The NF-kappa B and I kappa B proteins: new discoveries and insights
25. Interleukin-10 signaling blocks inhibitor of kB kinase activity and nuclear factor kB DNA binding
26. Early activation of transcription factor NF-kB during ischemia in perfused heart rat
27. Adenovirus-mediated expression of a mutant IkB kinase 2 inhibits the response of endothelial cells to inflammatory stimuli
28. Differential expression of neutrophil adhesion molecules during coronary artery surgery with cardiopulmonary bypass
29. The role of neutrophils in myocardial ischemia-reperfusion injury
30. Acute cardiac inflammatory response to postischemic reperfusion during cardiopulmonary bypass
31. Effects of extracorporeal circulation and heparin on the phenotype of platelet surface antigens following heart surgery
32. Apoptosis induced by ischemia and reperfusion in experimental lung transplantation
33. Death by design. Programmed cell death in cardiovascular biology and disease
34. Endothelial apoptosis is induced by serum of patients after cardiopulmonary bypass
35. The systemic inflammatory response to cardiopulmonary bypass: pathophysiological, therapeutic, and pharmacological considerations
36. Influence of methylprednisolone on cytokine balance during cardiac surgery
37. Does steroid pretreatment increase endotoxin release during clinical cardiopulmonary bypass?
38. Glucocorticoids blunt neutrophil CD11b surface glycoprotein upregulation during cardiopulmonary bypass in humans
39. Glucocorticoid modulation of human monocyte/macrophage function: control of TNF-alpha secretion
40. Glucocorticoids suppress TNF-α expression by human monocytic THP-1 cells by suppressing transactivation through adjacent NF-kB and c-Jun/ATF-2 binding sites in the promoter
41. Differential inhibitory actions by glucocorticoid and aspirin on cytokine-induced nitric oxide production in vascular smooth muscle cells
42. Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints
43. Aprotinin and methylprednisolone equally blunt cardiopulmonary bypass-induced inflammation in humans
44. Aprotinin is associated with a decrease in nitric oxide production during cardiopulmonary bypass
45. An anti-inflammatory property of aprotinin detected at the level of leukocyte extravasation
46. Aprotinin reduces Interleukin-8 production and lung neutrophil accumulation after cardiopulmonary bypass
47. Aprotinin attenuates platelet accumulation in ischemia-reperfusion-injured porcine skeletal muscle
48. Aprotinin pretreatment diminishes postischemic myocardial contractile dysfunction in dogs
49. Chloromethyl ketones block induction of nitric oxide synthase in murine macrophages by preventing activation of nuclear factor-kappa B
50. N-alpha-tosyl-L-lysine chloromethylketone prevents expression of iNOS in vascular smooth muscle by blocking activation of NF-kappa B
51. Inhibition of NF-kappaB activation and augmentation of IkappaBeta by secretory leukocyte protease inhibitor during lung inflammation
52. Cytokine release and neutrophil activation are not prevented by heparin-coated circuits and aprotinin administration
53. Anticoagulation and anticoagulation reversal with cardiac surgery involving cardiopulmonary bypass: an update
54. Thrombin generation during cardiac surgery: is heparin the ideal anticoagulant?
55. Heparin in inflammation: potential therapeutic applications beyond anticoagulation
56. Heparin oligosaccharides bind L- and P-selectin and inhibit acute inflammation
57. Heparin inhibits ligand binding to the leukocyte integrin Mac-1 (CD11/CD18)
58. The effects of heparin and related molecules upon the adhesion of human polymorphonuclear leukocytes to vascular endothelium in vitro
59. Cytokine gene expression in human LPS- and IFNγ-stimulated mononuclear cells is inhibited by heparin
60. Tumor necrosis factor measurement and use of different anticoagulants: possible interference in plasma samples and supernatants from endotoxin-stimulated monocytes
61. 2-macroglobulin
62. Heparin and nonanticoagulant heparin preserve regional myocardial contractility after ischemia-reperfusion injury: role of nitric oxide
63. Nonanticoagulant heparin prevents coronary endothelial dysfunction after brief ischemia-reperfusion injury in dog
64. Preventing bronchoconstriction in exercise-induced asthma with inhaled heparin
65. A multicenter, randomized, blind comparison of amrinone with milrinone after elective cardiac surgery
66. Vesnarinone and amrinone reduce systemic inflammatory response syndrome
67. Inhibitory effect of milrinone on cytokine production after cardiopulmonary bypass
68. Milrinone modulates endotoxemia, systemic inflammation, and subsequent acute phase response after cardiopulmonary bypass (CPB)
69. Influence of enoximone on systemic and splanchnic oxygen utilization and endotoxin release following cardiopulmonary bypass
70. Effective of preoperative supplementation with α-tocopherol and ascorbic acid on myocardial injury in patients undergoing cardiac operations
71. Vitamin E for coronary bypass operations. A prospective, double blind, randomized trial
72. Nitecapone as an additive to crystalloid cardioplegia in patients who had coronary artery bypass grafting
73. Nitecapone reduces cardiac neutrophil accumulation in clinical open heart surgery
74. A randomized, blinded trial of the antioxidant pegorgotein: no reduction in neuropsychological deficits, inotropic drug support, or myocardial ischemia after coronary artery bypass surgery
75. Inhibition of inducible nitric oxide synthase restores endothelium-dependent relaxations in proinflammatory mediator-induced blood vessels
76. Nitric oxide releasing-compounds inhibit neutrophil adhesion to endothelial cells
77. Inhibition by nitric oxide-releasing compounds of E-selectin expression in and neutrophil adhesion to human endothelial cells
78. Sodium nitroprusside: twenty years and counting
79. Effect of sodium nitroprusside on complement activation induced by cardiopulmonary bypass: a clinical and experimental study
80. Sodium nitroprusside during coronary artery bypass grafting: evidence for an antiinflammatory action
81. Sodium nitroprusside in patients with compromised left ventricular function undergoing coronary bypass: reduction of cardiac proinflammatory substances
82. Selective blockade of membrane attack complex formation during simulated extracorporeal circulation inhibits platelet but not leukocyte activation
83. Anti-c5a monoclonal antibodies reduces cardiopulmonary bypass and cardioplegia-induced coronary endothelial dysfunction
84. Pharmacology and biological efficacy of a recombinant, humanized, single chain antibody C5 complement inhibitor in patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass
85. x ameliorates ischemia/reperfusion injury in experimental lung transplantation
86. Heparin-coated circuits reduce the inflammatory response to cardiopulmonary bypass
87. Heparin-coated cardiopulmonary bypass equipment. I Biocompatibility markers and development of complications in high-risk population
88. Heparin-coated circuits reduce myocardial injury in heart or heart-lung transplantation: a prospective, randomized trials
89. Heparin coating of extracorporeal circuits inhibits contact activation during cardiac operations
90. Attenuation of changes in leukocyte surface markers and complement activation with heparin-coated cardiopulmonary bypass
91. Heparin-coated cardiopulmonary bypass equipment. II Mechanism for reduced complement activation in vivo
92. Heparin-coated circuits for high risk patients: a multicenter, prospective, randomized trial
93. Effects on coagulation and fibrinolysis with reduced versus full systemic heparinization and heparin-coated cardiopulmonary bypass
94. Complete heparin-coated (CBAS) cardiopulmonary bypass and reduced systemic heparin dose; effects on coagulation and fibrinolysis
95. More effective suppression of hemostatic system activation in patients undergoing cardiac surgery by heparin dosing based on a heparin blood concentration rather than ACT
96. Coagulofibrinolysis during heparin-coated cardiopulmonary bypass with reduced heparinization
97. Perioperative course and recovery after heparin-coated cardiopulmonary bypass: low dose versus high dose heparin management
98. No benefit of reduced heparinization in thoracic aortic operation with heparin-coated bypass circuits
99. Surface-bound heparin fails to reduce thrombin formation during clinical cardiopulmonary bypass
100. Cytokine and endothelial damage in pulsatile and nonpulsatile cardiopulmonary bypass
101. A clinical study on the effects of pulsatile cardiopulmonary bypass on the blood endotoxin levels
102. Endotoxemia, complement and white blood cells activation in cardiac surgery: a randomized trial of laxatives and pulsatile perfusion
103. Centrifugal pumps: description of devices and surgical techniques
104. Centrifugal pumps during routine open heart surgery improves clinical outcome
105. A comparison of the benefit of roller pump versus constrained vortex pump in adult open-heart operations utilizing outcomes research
106. Inflammatory mediators in adults undergoing cardiopulmonary bypass: comparison of centrifugal and roller pumps
107. Inflammatory response to cardiopulmonary bypass using roller or centrifugal pumps
108. A prospective randomized study of a modified technique of ultrafiltration during pediatric open-heart surgery
109. Hemofiltration in pediatric cardiac surgery
110. Modified ultrafiltration lowers adhesion molecules and cytokine levels after cardiopulmonary bypass without clinical relevance in adults
111. Effects of depletion of leukocytes and platelets on cardiac dysfunction after cardiopulmonary bypass
112. Leukocyte depletion during cardiac operation: a new approach through the venous bypass circuit
113. Does normothermia during cardiopulmonary bypass increase neutrophil-endothelium interactions?
114. Influence of temperature on neutrophil trafficking during clinical cardiopulmonary bypass
115. Hypothermia during cardiopulmonary bypass delays but does not prevent neutrophil-endothelial cell adhesion. A clinical study
116. Hypothermic versus normothermic cardiopulmonary bypass: influence on circulating adhesion molecules
117. The effects of cardiopulmonary bypass temperature on inflammatory response following cardiopulmonary
118. Role of nitric oxide in a temperature dependent regulation of systemic vascular resistance in cardiopulmonary bypass
119. Randomised trial of normothermic versus hypothermic coronary bypass surgery
120. Incidence of atrial fibrillation after mild or moderate hypothermic cardiopulmonary bypass
121. Intermittent antegrade warm cardioplegia reduces oxidative stress and improves metabolism of the ischemic-reperfused human myocardium
122. Intermittent antegrade tepid versus cold cardioplegia in elective myocardial revascularization
123. The effects of cardiopulmonary bypass temperature on neuropsychologic outcome after coronary artery operations: a prospective randomized trial
124. Cerebrovascular cytokine response during coronary artery bypass surgery: specific production of Interleukin-8 and its attenuation by hypothermic cardiopulmonary bypass
125. Hypothermic modulation of cerebral ischemic injury during cardiopulmonary bypass in pigs
126. Profound hypothermia in cardiac surgery. Report of three cases
127. Pulmonary function after biventricular bypass for autologous lung oxygenation
128. Drew-Anderson technique attenuates systemic inflammatory response syndrome and improves respiratory function after coronary artery bypass grafting
129. Pervanadate-induced Nuclear Factor kB activation requires tyrosine phosphorylation and degradation of I kBα. Comparison with Tumor Necrosis Factor α
130. Inhibition of the transcriptional activator protein nuclear factor kB prevents hemodynamic instability associated with the whole-body inflammatory response
131. A novel strategy of decoy transfection against nuclear factor-kB in myocardial preservation